Jefferies reiterates its 'buy' recommendation on Pfizer, but lowers its price target from $35 to $33, following the withdrawal of Oxbryta, a treatment for sickle-cell anemia, from all markets in parallel with the ongoing review by the European Medicines Agency (EMA).
The broker recalls that this decision was taken voluntarily by the pharmaceutical giant due to an imbalance between vaso-occlusive crises (VOC) and fatal events observed in the studies.
'Although it is unclear whether the mechanism of action (MOA) is at issue, we are removing both Oxbryta and GBT601 from our model pending further information', says Jefferies in the summary of its note.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.